<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4851">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01887002</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-2952POU005</org_study_id>
    <nct_id>NCT01887002</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)</brief_title>
  <acronym>RESTORE</acronym>
  <official_title>A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (RESTORE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharma USA Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to evaluate whether ONO-2952 modulates visceral pain perception produced by
      rectal distention in female patients with IBS-D
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in pain intensity rating during rectal distention by using a numeric pain rating scale</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessed through adverse events and clinical laboratory values</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Irritable Bowel Syndrome (IBS)</condition>
  <arm_group>
    <arm_group_label>Experimental Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONO-2952 Active tablets, every day for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ONO-2952 Matching Placebo every day for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-2952</intervention_name>
    <description>ONO-2952 Active tablets, every day for 2 weeks</description>
    <arm_group_label>Experimental Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>ONO-2952 Matching Placebo every day for 4 weeks</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female 18-65 years of age (inclusive)

          2. Diagnosed with IBS based on the following criteria (Rome III criteria):

               -  Symptom onset at least 6 months prior to diagnosis, and

               -  Recurrent abdominal pain or discomfort at least 3 days per month for the past 3
                  months, and

               -  Abdominal discomfort or pain associated with two or more of the following at
                  least 25% of the time:

               -  improvement with defecation

               -  onset associated with a change in frequency of stool/defecation

               -  onset associated with a change in form (appearance) of stool

          3. Diagnosed with IBS-D, defined as loose/watery stools ≥ 25% and hard/lumpy stools ≤
             25% of defecations

        Exclusion Criteria:

          -  Any structural abnormality of the gastrointestinal (GI) tract (other than esophagitis
             or gastritis)

          -  History of Chron's disease, ulcerative colitis, diabetes mellitus, lactose
             malabsorption, malabsorption syndromes, celiac sprue, or any upper GI symptoms that
             may impact the assessment of IBS symptoms
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ono Pharma USA, Inc.</last_name>
    <role>Study Director</role>
    <affiliation>Ono Pharmaceutical Co. Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheetal Patel</last_name>
    <email>s-patel@ono-uk.co.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boston Clinical Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Louis Clinical Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chapel Hill Clinical Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oklahoma City Clinical Site</name>
      <address>
        <city>Oklahoma</city>
        <state>Oklahoma</state>
        <zip>73160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>April 16, 2014</lastchanged_date>
  <firstreceived_date>June 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>IBS</keyword>
  <keyword>ONO-2952</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
